Marcus Mueller
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Marcus Mueller has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
- Evgenij V. Potapov
German Heart Center Berlin
5 shared publications - Volkmar Falk
Deutsches Herzzentrum der Charité, Charité University Medicine Berlin , Berlin
5 shared publications - Felix Schoenrath
Deutsches Herzzentrum der Charité, Klinik für Herz-, Thorax- und Gefäßchirurgie , Augustenburger Platz 1, 13353 Berlin
4 shared publications - Jan Knierim
Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum der Charité—Medical Heart Center of Charité and German Heart Institute Berlin, Augustenburger Platz 1, 13353 Berlin, Germany
4 shared publications Thomas Krabatsch
Department of Cardiothoracic and Vascular Surgery, German Heart Center Berlin, Berlin, Germany
4 shared publicationsChristoph Hoermandinger
Department of Cardiothoracic and Vascular Surgery, German Heart Center Berlin, Berlin, Germany
2 shared publications
Latest Publications
- 1 December 2022
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
- Vol. 164 (6) , 1922-1930.e2
Experience with a standardized protocol to predict successful explantation of left ventricular assist devices
- 1 December 2022
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
- Vol. 164 (6) , 1922-1930.e2
Experience with a standardized protocol to predict successful explantation of left ventricular assist devices
- Open Access
Left Ventricular Assist Device Implantation in Cancer-Therapy-Related Heart Failure
Objectives: Cancer-therapy-related heart failure (CTrHF) due to cardiotoxic drugs or radiation is a growing cause of end-stage heart failure. Limited knowledge is available concerning the use of continuous-flow left-ventricular-assist devices (cfLVAD) in this setting. Methods: The files of all 1334 patients who underwent cfLVAD implantation between December 2008 and December 2020 were screened for the cause of heart failure. All patients with CTrHF were included in the analysis. Results: A total of 32 patients with a median age of 58 years (IQR: 46–65) were included in the study; 15 (47%) were male. The median time from the first diagnosis of heart failure (HF) to cfLVAD implantation was 6 months (IQR 2–24), and from cancer treatment to cfLVAD implantation 40 months (IQR 5–144). Malignancies comprised non-Hodgkin lymphoma (n = 12, 37%), breast cancer (n = 9, 28%), sarcoma (n = 5, 16%), leukemia (n = 5, 16%), and others (n = 1, 3%). In 24 patients, chemotherapy included anthracyclines (others n = 2, unknown n = 6). Chest radiation was performed in 13 patients (39%). Moreover, 71% were classified as INTERMACS profile 1 or 2. The 30-day survival rate after LVAD implantation was 88%. Rethoracotomy was necessary in nine (29%), and a temporary right ventricular assist device in seven (21%) patients. The median survival was 29 months. There was no significant difference in survival or right HF between patients with CTrHF and a matched control group. Conclusions: CfLVAD implantation is feasible in high-risk patients with CTrHF with or without prior chest radiation.
Open AccessLeft Ventricular Assist Device Implantation in Cancer-Therapy-Related Heart Failure
Objectives: Cancer-therapy-related heart failure (CTrHF) due to cardiotoxic drugs or radiation is a growing cause of end-stage heart failure. Limited knowledge is available concerning the use of continuous-flow left-ventricular-assist devices (cfLVAD) in this setting. Methods: The files of all 1334 patients who underwent cfLVAD implantation between December 2008 and December 2020 were screened for the cause of heart failure. All patients with CTrHF were included in the analysis. Results: A total of 32 patients with a median age of 58 years (IQR: 46–65) were included in the study; 15 (47%) were male. The median time from the first diagnosis of heart failure (HF) to cfLVAD implantation was 6 months (IQR 2–24), and from cancer treatment to cfLVAD implantation 40 months (IQR 5–144). Malignancies comprised non-Hodgkin lymphoma (n = 12, 37%), breast cancer (n = 9, 28%), sarcoma (n = 5, 16%), leukemia (n = 5, 16%), and others (n = 1, 3%). In 24 patients, chemotherapy included anthracyclines (others n = 2, unknown n = 6). Chest radiation was performed in 13 patients (39%). Moreover, 71% were classified as INTERMACS profile 1 or 2. The 30-day survival rate after LVAD implantation was 88%. Rethoracotomy was necessary in nine (29%), and a temporary right ventricular assist device in seven (21%) patients. The median survival was 29 months. There was no significant difference in survival or right HF between patients with CTrHF and a matched control group. Conclusions: CfLVAD implantation is feasible in high-risk patients with CTrHF with or without prior chest radiation.
- 1 December 2021
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 27 (12) , 1328-1336
Safety of Contemporary Heart Failure Therapy in Patients with Continuous-Flow Left Ventricular Assist Devices
- 1 December 2021
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 27 (12) , 1328-1336
Safety of Contemporary Heart Failure Therapy in Patients with Continuous-Flow Left Ventricular Assist Devices
- Open Access
- 1 September 2020
- Published by Oxford University Press (OUP) in Journal of Surgical Case Reports
- Vol. 2020 (9)
Extended right posterior liver sectionectomy for HCC in a patient with left ventricular assist device—a case report
Successful implementation of left ventricular assist devices lead to a prolonged survival in patients with chronic terminal heart failure. Thus, patients with pre-existing left ventricular assist devices with abdominal comorbidities requiring abdominal surgery, e.g. for malignancy, are upcoming issues. We carried out a major liver resection for hepatocellular carcinoma in a patient with pre-existing left ventricular assist device. The importance of this case report is that it outlines the significance of oncologic resections in patients with left ventricular assist devices as an upcoming issue and provides an interdisciplinary approach.
- 1 September 2020
- Published by Oxford University Press (OUP) in Journal of Surgical Case Reports
- Vol. 2020 (9)
Open AccessExtended right posterior liver sectionectomy for HCC in a patient with left ventricular assist device—a case report
Successful implementation of left ventricular assist devices lead to a prolonged survival in patients with chronic terminal heart failure. Thus, patients with pre-existing left ventricular assist devices with abdominal comorbidities requiring abdominal surgery, e.g. for malignancy, are upcoming issues. We carried out a major liver resection for hepatocellular carcinoma in a patient with pre-existing left ventricular assist device. The importance of this case report is that it outlines the significance of oncologic resections in patients with left ventricular assist devices as an upcoming issue and provides an interdisciplinary approach.
- Open Access
- 1 August 2020
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 58 (2) , 410
Retrospective 1-year outcome follow-up in 200 patients supported with HeartMate 3 and HeartWare left ventricular assist devices in a single centre (vol 57, pg 1160, 2020)
In the originally published version of this article, the value of the 95% confidence interval in the last line of the results of the abstract and in the last paragraph of the main results section should read: 95% CI (0.58–0.767).
- 1 August 2020
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 58 (2) , 410
Open AccessRetrospective 1-year outcome follow-up in 200 patients supported with HeartMate 3 and HeartWare left ventricular assist devices in a single centre (vol 57, pg 1160, 2020)
In the originally published version of this article, the value of the 95% confidence interval in the last line of the results of the abstract and in the last paragraph of the main results section should read: 95% CI (0.58–0.767).
- Open Access
- 16 April 2020
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 57 (6) , 1160-1165
Retrospective 1-year outcome follow-up in 200 patients supported with HeartMate 3 and HeartWare left ventricular assist devices in a single centre
OBJECTIVES: Various trials have assessed the outcome and reliability of the HeartWare HVAD (HW) and HeartMate 3 (HM3) left ventricular assist devices. A direct comparison of clinical outcomes and of the complication profile of these 2 left ventricular assist devices is lacking. We present a retrospective analysis of patients supported with HM3 and HW as a left ventricular assist device. METHODS: Preoperative data, complications and outcomes including a 1-year follow-up of patients supported with the HM3 and HW in a single centre were retrospectively analysed. Both pumps were implanted on- or off-pump, employing standard and minimally invasive techniques. For logistic reasons, the 2 device types were implanted in an alternating manner, thereby reducing the systematic bias for pump selection. We considered this to be an appropriate approach, as no differences in respect of survival or the complication profile of the two device types have been demonstrated. Anticoagulation was similar in patients with both pumps according to our anticoagulation protocol, with a target international normalized ratio of 2.5–3.0, a home monitoring system and blood pressure management with a mean arterial target pressure of 70–80 mmHg. RESULTS: Between October 2015 and April 2017, 100 patients underwent implantation of the HW and 100 patients underwent implantation of the HM3. The median time on the device was 0.98 years (range 0–2.23 years). The median age was 58.5 (51–65) versus 57 (49–64) years (P = 0.456); the number of male patients was 87 versus 88 (P = 0.831). Of the HW patients, 73% were rated as having an INTERMACS level I or II, compared to 57% of the HM3 patients (P = 0.018). There were no further differences in preoperative data. A total of 14 patients had pre-, intra- or post-pump blood flow obstruction in the HW group versus 4 in the HM3 group [hazard ratio (HR) 2.5 (0.7–8.8), P = 0.103]. There were no differences regarding gastrointestinal bleeding [HR 1.25 (0.56–2.64), P = 0.624] or driveline infection (0.68 vs 0.8 events per patient-year, P = 0.0789). The incidence of ischaemic stroke was similar in both groups [HR 0.72 (0.25–2.09), P = 0.550]. Cerebral bleeding was more frequent in patients supported with HW [HR 6.79 (1.43–32.20), P = 0.016]. The incidence of cerebrovascular accidents, on the other hand, was similar in both groups [HR 1.85 (0.83–4.19), P = 0.13]. The incidence of haemocompatibility-related adverse events, however, was significantly higher in the HW group (113 points corresponding to 1.28 events per patient-year versus 69 points corresponding to 0.7 events per patient-year, P < 0.001). The 1-year survival was similar in both groups [62.2%, 95% confidence interval (CI) (0.53–0.73) vs 66.7%, 95% CI (0.58–0.767), P = 0.372]. CONCLUSIONS: Our data show that the complication profile differs between the 2 pumps, but that early survival is comparable.
- 16 April 2020
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 57 (6) , 1160-1165
Open AccessRetrospective 1-year outcome follow-up in 200 patients supported with HeartMate 3 and HeartWare left ventricular assist devices in a single centre
OBJECTIVES: Various trials have assessed the outcome and reliability of the HeartWare HVAD (HW) and HeartMate 3 (HM3) left ventricular assist devices. A direct comparison of clinical outcomes and of the complication profile of these 2 left ventricular assist devices is lacking. We present a retrospective analysis of patients supported with HM3 and HW as a left ventricular assist device. METHODS: Preoperative data, complications and outcomes including a 1-year follow-up of patients supported with the HM3 and HW in a single centre were retrospectively analysed. Both pumps were implanted on- or off-pump, employing standard and minimally invasive techniques. For logistic reasons, the 2 device types were implanted in an alternating manner, thereby reducing the systematic bias for pump selection. We considered this to be an appropriate approach, as no differences in respect of survival or the complication profile of the two device types have been demonstrated. Anticoagulation was similar in patients with both pumps according to our anticoagulation protocol, with a target international normalized ratio of 2.5–3.0, a home monitoring system and blood pressure management with a mean arterial target pressure of 70–80 mmHg. RESULTS: Between October 2015 and April 2017, 100 patients underwent implantation of the HW and 100 patients underwent implantation of the HM3. The median time on the device was 0.98 years (range 0–2.23 years). The median age was 58.5 (51–65) versus 57 (49–64) years (P = 0.456); the number of male patients was 87 versus 88 (P = 0.831). Of the HW patients, 73% were rated as having an INTERMACS level I or II, compared to 57% of the HM3 patients (P = 0.018). There were no further differences in preoperative data. A total of 14 patients had pre-, intra- or post-pump blood flow obstruction in the HW group versus 4 in the HM3 group [hazard ratio (HR) 2.5 (0.7–8.8), P = 0.103]. There were no differences regarding gastrointestinal bleeding [HR 1.25 (0.56–2.64), P = 0.624] or driveline infection (0.68 vs 0.8 events per patient-year, P = 0.0789). The incidence of ischaemic stroke was similar in both groups [HR 0.72 (0.25–2.09), P = 0.550]. Cerebral bleeding was more frequent in patients supported with HW [HR 6.79 (1.43–32.20), P = 0.016]. The incidence of cerebrovascular accidents, on the other hand, was similar in both groups [HR 1.85 (0.83–4.19), P = 0.13]. The incidence of haemocompatibility-related adverse events, however, was significantly higher in the HW group (113 points corresponding to 1.28 events per patient-year versus 69 points corresponding to 0.7 events per patient-year, P < 0.001). The 1-year survival was similar in both groups [62.2%, 95% confidence interval (CI) (0.53–0.73) vs 66.7%, 95% CI (0.58–0.767), P = 0.372]. CONCLUSIONS: Our data show that the complication profile differs between the 2 pumps, but that early survival is comparable.
- Open Access
- 1 April 2020
- Published by Elsevier in Journal of Critical Care
- Vol. 56, 106-112
Prevention and early treatment of driveline infections in ventricular assist device patients – The DESTINE staging proposal and the first standard of care protocol
- 1 April 2020
- Published by Elsevier in Journal of Critical Care
- Vol. 56, 106-112
Open AccessPrevention and early treatment of driveline infections in ventricular assist device patients – The DESTINE staging proposal and the first standard of care protocol
- 1 April 2019
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 38 (4) , 440-448
Outcomes from a recovery protocol for patients with continuous-flow left ventricular assist devices
- 1 April 2019
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 38 (4) , 440-448
Outcomes from a recovery protocol for patients with continuous-flow left ventricular assist devices